T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus

This study has been completed.
Sponsor:
Information provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
ClinicalTrials.gov Identifier:
NCT00212329
First received: September 13, 2005
Last updated: January 31, 2011
Last verified: January 2011
  Purpose

Type 1 diabetes is a condition that is caused in part by an abnormality of the immune system which occurs when T cells, which are part of the immune system, damage the insulin secreting cells (islet cells) in the pancreas. Although it is known that T cells are important mediators of the disease, progress in the development of reliable T cell assays has been modest. The purpose of this study is to learn which T cell assays are most reliable and reproducible so that the investigators can improve their understanding about how type 1 diabetes occurs.


Condition Intervention
Type 1 Diabetes Mellitus
Procedure: T Cell Proliferation and Autoreactivity Assays
Procedure: Cellular Immunoblot Assays
Procedure: Tetramer Studies
Procedure: Cytokine ELISPOT

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus

Resource links provided by NLM:


Further study details as provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):

Estimated Enrollment: 100
Study Start Date: September 2005
Study Completion Date: September 2007
Detailed Description:

The T Cell Validation Study is designed to determine the ability of T cell assays to identify differences in responses from participants with type 1 diabetes compared to normal control subjects, and to compare four different laboratory tests which examine T cells to determine whether the measurements are quantitatively reproducible.

Antibody assays that confirm the presence of type 1 diabetes will be evaluated including: Diabetes Biochemical Autoantibody Assay (anti-GAD65, anti-ICA512, anti-insulin) and Islet Cell Autoantibody testing; genetic testing (deoxyribonucleic acid [DNA] and human leukocyte antigen [HLA]) will also be done to learn more about the T cell assays.

The following T Cell Assays will be conducted in individuals with type 1 diabetes, as well as those without type 1 diabetes:

  • Cellular Immunoblot Testing
  • T Cell Proliferation Assay
  • Tetramer Assay
  • Cytokine ELISpot Assay
  Eligibility

Ages Eligible for Study:   8 Years to 35 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

To be eligible, individuals with type 1 diabetes must be:

  • Diagnosed with type 1 diabetes within one year of first study visit
  • 8-35 years of age at time of first visit
  • Weigh > 40 kg (88 lbs) at time of first visit
  • Individuals who will serve as control subjects who do not have type 1 diabetes cannot have a first degree or second degree relative with type 1 diabetes.

Exclusion Criteria:

Individuals must not:

  • Have any major illness
  • Be taking any steroid medications
  • If female, should not be pregnant or breastfeeding.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00212329

Locations
United States, California
Childrens Hospital of Los Angeles
Los Angeles, California, United States, 90027
University of California, San Francisco
San Francisco, California, United States, 94143-0136
Stanford University Medical Center
Stanford, California, United States, 94305-5208
United States, Colorado
Barbara Davis Center for Childhood Diabetes
Denver, Colorado, United States, 80010
United States, Florida
University of Florida
Gainesville, Florida, United States, 32608
University of Miami School of Medicine
Miami, Florida, United States, 33136
United States, Indiana
Riley Hospital for Children
Indianapolis, Indiana, United States, 46202
United States, Massachusetts
Joslin Diabetes Center
Boston, Massachusetts, United States, 02215
United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55455
United States, New York
Naomi Berrie Diabetes Center, Columbia University
New York, New York, United States, 10032
United States, Pennsylvania
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania, United States, 15213
United States, Texas
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas, United States, 75235
United States, Washington
Benaroya Research Institute at Virginia Mason
Seattle, Washington, United States, 98101
United Kingdom
University of Bristol
Bristol, United Kingdom, BS10 5NB
Sponsors and Collaborators
Investigators
Study Chair: Jay E Skyler, MD Type 1 Diabetes TrialNet Study Chairman
  More Information

Publications:

ClinicalTrials.gov Identifier: NCT00212329     History of Changes
Other Study ID Numbers: Tcell (IND) (completed)
Study First Received: September 13, 2005
Last Updated: January 31, 2011
Health Authority: United States: Federal Government

Keywords provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):
Type 1 Diabetes
Juvenile Onset Diabetes
Insulin Dependent Diabetes
T1D

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases

ClinicalTrials.gov processed this record on August 28, 2014